Our NME's contain molecular conjugates designed to join two separate bioactives into a single NME. In systemic circulation, the molecular conjugates are designed to be cleaved by specific enzymes in order to release the two bioactives. By releasing the bioactive components of the conjugate molecule allows the bioactives to reach their targets more efficiently and have greater efficacy than if the bioactives were dosed independently or in combination.The new molecular entities ("NMEs") dissociate completely in the GI tract to deliver high plasma and tissue levels of active molecule in the free individual bioactive form.

Download Brochure

VCB-101: Novel conjugate of monomethyl fumarate (MMF)

  • A Novel Ester Conjugate of MMF and EPA for the treatment of Multiple Sclerosis and Psoriasis
  • Designed for slow and sustained release of the actives
  • Targeted to reduce GI side-effect profile and also Dose Dependent Flushing of DimethylFumarate
  • Pre-Clinical: Completion and Currently at IND filing stage
  • Regulatory: 505(b)(2) Pathway
  • Intellectual Property: Issued US Patent. National Stage Filings were filed in 12 countries with their respective PTO’s
VCB-101 Indications:
  • Relapsing Remitting Multiple Sclerosis (RRMS)
  • Psoriasis

Mechanism: VCB-101 is

  • prodrug of monomethyl fumarate (MMF) that activates a transcription factor called the nuclear factor (erythroid-derived 2)-like 2, also known as NFE2L2 or Nrf2

 

VCB-102: Novel conjugate of monomethyl fumarate (MMF)

  • A Novel Conjugate of MMF for the treatment Psoriasis
  • Designed for slow and sustained release of the actives
  • Targeted to reduce GI side-effect profile and also Dose Dependent Flushing of DimethylFumarate
  • Intellectual Property: Issued US Patent. National Stage Filings were filed.
VCB-102 Indications:
  • Psoriasis

Mechanism: VCB-102 is

  • prodrug of monomethyl fumarate (MMF) that activates a transcription factor called the nuclear factor (erythroid-derived 2)-like 2, also known as NFE2L2 or Nrf2